Empagliflozin did not significantly reduce overall HF hospitalization or all-cause death in high-risk patients in EMPACT-MI but did reduce first and total hospitalizations.
SGLT2 inhibitors not only were safe in adult patients with congenital heart disease who develop heart failure but also were associated with reduced hospitalizations.
SGLT2 inhibitors are known to reduce diabetic nephropathy risk in patients with type 2 diabetes, but can they also protect against diabetic retinopathy?
Sodium-glucose cotransporter-2 inhibitors are not approved to treat gout, lupus, or lupus nephritis, but clinicians are uncovering signs of benefits in these conditions.